


Supplementary Fig. S1. Data augmentation by changing colors randomly.



Supplementary Fig. S2. Architecture of deep learning models.



Supplementary Fig. S3. Tumor mutational burden of each subgroup. Patients were classified into EBV, MSI/dMMR, and others by the prediction of our deep learning model (a) or by the ground truth (b). *: p<0.001, Welch's t-test. EBV- Epstein-Barr virus, MSI- microsatellite instability, dMMR- mismatch repair deficiency.



Supplementary Table S1. Checklist of STARD guideline.

Section & Topic No Item

TITLE OR ABSTRACT			
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values, or AUC)	2
ABSTRACT			
	2	Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)	2-3
INTRODUCTION			
	3	Scientific and clinical background, including the intended use and clinical role of the index test	4-6
	4	Study objectives and hypotheses	6
METHODS			
Study design	5	Whether data collection was planned before the index test and reference standard	6-8
		were performed (prospective study) or after (retrospective study)	
Participants	6	Eligibility criteria	6-8
	7	On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)	6-8
	8	Where and when potentially eligible participants were identified (setting, location and dates)	6-8
	9	Whether participants formed a consecutive, random or convenience series	6-8
Test methods	10a	Index test, in sufficient detail to allow replication	8-13
	10b	Reference standard, in sufficient detail to allow replication	7-8
	11	Rationale for choosing the reference standard (if alternatives exist)	Not applicable
	12a	Definition of and rationale for test positivity cut-offs or result categories	12
		of the index test, distinguishing pre-specified from exploratory	
	12b	Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory	Not applicable
	13a	Whether clinical information and reference standard results were available	29
		to the performers/readers of the index test	
	13b	Whether clinical information and index test results were available	Not applicable

			•
		to the assessors of the reference standard	
Analysis	14	Methods for estimating or comparing measures of diagnostic accuracy	12-13
	15	How indeterminate index test or reference standard results were handled	Not applicable
	16	How missing data on the index test and reference standard were handled	Not applicable
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory	12-13
	18	Intended sample size and how it was determined	6-7
RESULTS			
Participants	19	Flow of participants, using a diagram	7-8, Fig.2
	20	Baseline demographic and clinical characteristics of participants	14, Table 1
	21a	Distribution of severity of disease in those with the target condition	14, Table 1
	21b	Distribution of alternative diagnoses in those without the target condition	14, Table 1
	22	Time interval and any clinical interventions between index test and reference standard	Not applicable
Test results	23	Cross tabulation of the index test results (or their distribution) by the results of the reference standard	24 (online data)
	24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	15-16
	25	Any adverse events from performing the index test or the reference standard	Not applicable
DISCUSSION			
	26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	23
	27	Implications for practice, including the intended use and clinical role of the index test	22
OTHER INFORMATION			
	28	Registration number and name of registry	Not applicable
	29	Where the full study protocol can be accessed	Not applicable
	30	Sources of funding and other support; role of funders	Not applicable

Supplementary Table S2. Hyperparameters used for training deep learning models.

	VGG16-based		VGG19-based		ResNet50-based		EfficientNetB0-based	
	Transfer	Successive	Transfer	Successive	Transfer	Successive	Transfer	Successive
	learning	fine tuning	learning	fine tuning	learning	fine tuning	learning	fine tuning
Batch size	256	256	256	256	256	256	256	256
Optimizer	Adam	SGD	Adam	SGD	Adam	SGD	Adam	SGD
Learning	1.0×10 ⁻³ 2.0×10 ⁻⁵	1.0×10 ⁻³	2.0×10-5	1.0×10 ⁻³	2.0×10 ⁻⁵	1.0×10 ⁻³	1.0×10-4	
rate		J^10° 2.0*10°	1.0×10°	2.0×10⁻⁵	1.0^10°	2.0^10 °	1.0^10°	1.0×10 ⁻⁴
Cumulative								
total								
number of	1,280,000	2 5 9 4 0 0 0	1 290 000	4,275,200	F12 000	2 5 9 4 0 0 0	512,000	5,990,400
images	1,200,000	3,584,000	1,280,000	4,275,200	512,000	3,584,000	512,000	5,990,400
used for								
training								

Deep learning models were first trained with convolution layers frozen (transfer learning), and then trained entirely with small learning rate (successive fine tuning).

Parameters	TCGA (training)	TCGA (test)	TCGA (all)
Total number of samples	48	196	244
Molecular classification			
EBV	5 (10.4%)	18 (9.2%)	23 (9.4%)
MSI/dMMR	8 (16.7%)	36 (18.4%)	44 (18.0%)
Others	35 (72.9%)	142 (72.4%)	177 (72.5%)
CIN	25 (52.1%)	102 (52.0%)	127 (52.0%)
GS	10 (20.8%)	40 (20.4%)	50 (20.5%)
Lauren classification for			
EBV-negative and			
microsatellite stable			
tumors			
Intestinal	22 (62.9%)	92 (64.8%)	114 (64.4%)
Diffuse	10 (28.6%)	41 (28.9%)	51 (28.8%)
Mixed	3 (8.6%)	8 (5.6%)	11 (6.2%)
NA	0 (0.0%)	1 (0.7%)	1 (0.6%)
pT stage			
pT1	0 (0.0%)	9 (4.6%)	9 (3.7%)
pT2	6 (12.5%)	30 (15.3%)	36 (14.8%)
pT3	32 (66.7%)	110 (56.1%)	142 (58.2%)
pT4	10 (20.8%)	47 (24.0%)	57 (23.4%)

Supplementary Table S3. Pathological information of cohorts included in this study.

TCGA, The cancer genome atlas; EBV, Epstein-Barr virus; MSI, Microsatellite instability; dMMR, mismatch repair deficiency; CIN, chromosomal instable; GS, genomically stable; NA, not available.